A new weapon against the tobacco industry : class action lawsuit using a novel epidemiologic parameter
- document 1 document 2 document 3
- niveau 1 niveau 2 niveau 3
- audio 1 audio 2 audio 3
Descriptif
Epidemiologyand public health
Lawsuits against thetobacco industry, if successful, have the potential to compensate victims ofsmoking and to diminish the capacity of the tobacco industry to continue tofunction with impunity. Up to now, the only successful legal actions againstBig Tobacco have been those brought on behalf of states or provinces to recovernational health care costs associated with tobacco diseases, and those broughton behalf of individual victims, in which financial damages were sought.
Class action lawsuitsto recover damages on behalf of the huge numbers of victims have not previouslybeen successful. The problem is that the tobacco industry has successfullyargued that such a lawsuit requires a demonstration of “more likely than not”causation for each plaintiff. Depending on the jurisdiction, there may be manythousands or millions of incident cases annually, and it is impossible to bringthem all into court individually to determine whether smoking was “more likelythan not” a contributing cause of each case.
Fifteen years ago,class action suit was launched in Quebec on behalf of all lung cancer patientswhose disease was caused by cigarette smoking. The plaintiffs’ lawyers asked meto estimate how many cases of cancer were caused by smoking. This sounds likethe classic attributable fraction in epidemiology. But upon refinement, thequestion became one that has not previously been addressed in epidemiology:What proportion of lung cancer cases in Quebec, if they hypothetically could beindividually evaluated, would satisfy the “more likely than not” criterion?
The novel methodologyI developed is based on two stages. First I estimated the dose-responserelationship between smoking and lung cancer, for which I use the pack-years asa measure of smoking. I define the amount of smoking that is required to inducea two-fold risk as the “critical amount” that makes it more likely than notthat smoking contributed to the cancer. Depending on the model used andconsidering statistical variability, I estimated that the critical amountrequired to double the risk was somewhere between 5 and 12 pack-years ofsmoking.
Then I had toestimate what fraction of Quebec lung cancer patients had smoked more than thecritical amount. I estimated this to be over 90%.
The Quebec trial, atwhich I testified and was cross-examined at length and criticized by a paradeof defense witnesses, ended in 2014. The judge has made his judgement. Hesupported the plaintiffs. I will describe some aspects of the trial.
Cette présentation a été donnée dans le cadre du BRIO SIRICscientific day 3 organisé annuellement par le SIRIC BRIO et qui a pour but deréunir tous les acteurs du SIRIC BRIO et plus largement de la cancérologie àBordeaux.
Intervenants
Thèmes
Notice
Dans la même collection
-
-
A combined laser microdissection and mass spectrometry method for proteomic analysis of tissue sect…RaymondAnne-Aurélie
Clinical and biological samples : opportunities and challenges for translational research A challenge in oncology is to better define the tumor of the patient to study the pathology and of course
-
From the OR to clinical database... what for ? The example of UroCCRBernhardJean-Christophe
Clinical and biological samples : opportunities and challenges for translational research The UroCCR database was created to respond to the need on centralization and sharing of the multiple
-
Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomasLe Guyader-PeyrouSandra
Epidemiology and public health The principal aim of this thesis will describe the care pathway of diffuse large B cell lymphoma (DBCL) and follicular lymphoma (FL) in the general population and
-
Modelling prognostic capabilities of tumor size : application to colorectal cancerRondeauVirginie
Epidemiology and public health In oncology, the international WHO and RECIST criteria have allowed the standardization of tumor response evaluation in order to identify the time of disease
-
How studying hematological malignancies subtypes may inform epidemiologic and clinical researchMonnereauAlain
Epidemiology and public health The aim of the talk entitled "How studying hematological malignancies (HM) subtypes may inform epidemiologic and clinical research" is to bring to the audience
-
Flash talk - Call for proposal FAC 2014ElustondoFrédéricWodrichHaraldFaustinBenjaminSaltelFrédéricCognetLaurent
Personalized breast cancer therapy based on viral functional assays to score pathway activity Harald Wodrich, University of Bordeaux State-of-the-art mass sequencing technology has paved the road
-
BRIO supporting action to integrated cancer research in BordeauxMeoniPaolo
About BRIO Siric challenges and actions The success of BRIO’s approach and the realization of its potential impact on the translational research community in Bordeaux rely both on the efficient
-
Sarcoma Database: a unique tool for research on mesenchymal tumorsCoindreJean-Michel
Clinical biology session The main sarcoma databases are the Conticabase (https://conticabase.sarcomabcb.org) and the ConticaGist (https://conticagist.sarcomabcb.org) with 18000 patients and which
-
BRIO strategic challenges and the implementation of a translational culture in BordeauxSoubeyranPierre
About BRIO Siric challenges and actions BRIO’s strategic objective is to strengthen Bordeaux’s leadership in Cancer Research through the creation of a dynamic cancer research community, the
-
Experts panel discussion: What opportunities and best practices for the use of clinical material in…
En point d'orgue du Scientific BRIO Day, David Cameron, spécialiste reconnu en Oncologie, Professeur à l'Université d'Edimbourg, anime un débat sur la question des opportinités et bonnes pratiques
Sur le même thème
-
JPS 2017 / Dépistage en médecine générale
Journées des Professionnels de Santé 2017 Formation Médicale Continue des Médecins Généralistes >> Yves-Marie Vincent : Dépistage du cancer du sein >> Emmanuel Prothon et
-
-
A combined laser microdissection and mass spectrometry method for proteomic analysis of tissue sect…RaymondAnne-Aurélie
Clinical and biological samples : opportunities and challenges for translational research A challenge in oncology is to better define the tumor of the patient to study the pathology and of course
-
From the OR to clinical database... what for ? The example of UroCCRBernhardJean-Christophe
Clinical and biological samples : opportunities and challenges for translational research The UroCCR database was created to respond to the need on centralization and sharing of the multiple
-
Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomasLe Guyader-PeyrouSandra
Epidemiology and public health The principal aim of this thesis will describe the care pathway of diffuse large B cell lymphoma (DBCL) and follicular lymphoma (FL) in the general population and
-
Modelling prognostic capabilities of tumor size : application to colorectal cancerRondeauVirginie
Epidemiology and public health In oncology, the international WHO and RECIST criteria have allowed the standardization of tumor response evaluation in order to identify the time of disease
-
How studying hematological malignancies subtypes may inform epidemiologic and clinical researchMonnereauAlain
Epidemiology and public health The aim of the talk entitled "How studying hematological malignancies (HM) subtypes may inform epidemiologic and clinical research" is to bring to the audience
-
Flash talk - Call for proposal FAC 2014ElustondoFrédéricWodrichHaraldFaustinBenjaminSaltelFrédéricCognetLaurent
Personalized breast cancer therapy based on viral functional assays to score pathway activity Harald Wodrich, University of Bordeaux State-of-the-art mass sequencing technology has paved the road
-
Sarcoma Database: a unique tool for research on mesenchymal tumorsCoindreJean-Michel
Clinical biology session The main sarcoma databases are the Conticabase (https://conticabase.sarcomabcb.org) and the ConticaGist (https://conticagist.sarcomabcb.org) with 18000 patients and which
-
BRIO supporting action to integrated cancer research in BordeauxMeoniPaolo
About BRIO Siric challenges and actions The success of BRIO’s approach and the realization of its potential impact on the translational research community in Bordeaux rely both on the efficient
-
BRIO strategic challenges and the implementation of a translational culture in BordeauxSoubeyranPierre
About BRIO Siric challenges and actions BRIO’s strategic objective is to strengthen Bordeaux’s leadership in Cancer Research through the creation of a dynamic cancer research community, the
-
Experts panel discussion: What opportunities and best practices for the use of clinical material in…
En point d'orgue du Scientific BRIO Day, David Cameron, spécialiste reconnu en Oncologie, Professeur à l'Université d'Edimbourg, anime un débat sur la question des opportinités et bonnes pratiques